Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082875 · ClinicalTrials.gov registry record · Phase 2
Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT00082875: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00082875 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 56 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00082875, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
This randomized phase II trial is studying how well cilengitide works in treating patients with unresectable stage III or stage IV melanoma. Cilengitide may stop the growth of melanoma by stopping blood flow to the tumor.
Primary Outcome
Each dose of EMD 121974 will be analyzed separately.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG cilengitide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2004-03 |
| Phase | Phase 2 |
Why NCT00082875 stopped before completion
NCT00082875 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00082875 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00082875 about?
NCT00082875 is a clinical study titled "Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma". This randomized phase II trial is studying how well cilengitide works in treating patients with unresectable stage III or stage IV melanoma. Cilengitide may stop the growth of melanoma by stopping blood flow to the tumor.
What is the current status of trial NCT00082875?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2004-03.
What interventions are being tested in trial NCT00082875?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), cilengitide (DRUG).
Who is sponsoring clinical trial NCT00082875?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00082875's enrollment target sits among peer trials
56 1146th of 2000 higher than 848 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia